Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701)

Study of Venetoclax (ABT199) Plus Chemoimmunotherapy for MYC/BCL2 Double-Hit and Double Expressing Lymphomas (A051701)

Trial Category:
Lymphoma
Phase
II
Contact(s)
Mary Beth Wilwerding, RN
Phone
402-991-8070
Fax
402-991-8850
Location(s)
Methodist Estabrook Cancer Center, Omaha, NE
 
 
Become a NOS Member Today!
 

Platinum Corporate Members

Gold Corporate Members